Liraglutide reduces lipid accumulation in steatotic L 02 cells by enhancing autophagy

Molecular Medicine Reports

Volumn 10, Issue 5, 2014, Pages 2351-2357

  Zhou, Shi Wei ^a   Zhang, Man ^a   Zhu, Min ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Autophagy; Glucagon like peptide 1; Hepatic steatosis; Liraglutide; Non alcoholic fatty liver disease

Indexed keywords

3 METHYLADENINE; FATTY ACID; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; LIRAGLUTIDE; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN 1; RAPAMYCIN; TRIACYLGLYCEROL; GLUCAGON LIKE PEPTIDE 1;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL VIABILITY; CONTROLLED STUDY; ELECTRON MICROSCOPY; FATTY LIVER; HUMAN; HUMAN CELL; LIPID STORAGE; LIVER CELL; OXIDATIVE STRESS; TREATMENT OUTCOME; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CELL LINE; DRUG EFFECTS; DRUG SCREENING; LIPID METABOLISM; LIVER; METABOLISM; PATHOLOGY;

AUTOPHAGY; CELL LINE; DRUG EVALUATION, PRECLINICAL; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LIPID METABOLISM; LIVER; OXIDATIVE STRESS;

EID: 84907187411     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2569     Document Type: Article

References (26)

1. Cohen JC, Horton JD and Hobbs HH: Human fatty liver disease: old questions and new insights. Science 332: 1519-1523, 2011.
2. Ferre P and Foufelle F: Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 12 Suppl 2: 83-92, 2010.
3. Gentile CL, Frye MA and Pagliassotti MJ: Fatty acids and the endoplasmic reticulum in nonalcoholic fatty liver disease. Biofactors 37: 8-16, 2011.
4. LL and Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157, 2007.
5. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK and Elahi D: Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 94: 1843-1852, 2009.
6. Svegliati-Baroni G, Saccomanno S, Rychlicki C, et al: Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 31: 1285-1297, 2011.
7. Gupta NA, Mells J, Dunham RM, et al: Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51: 1584-1592, 2010.
8. Ding X, Saxena NK, Lin S, Gupta NA and Anania FA: Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43: 173-181, 2006.
9. Sharma S, Mells JE, Fu PP, Saxena NK and Anania FA: GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One 6: e25269, 2011.
10. Ben-Shlomo S, Zvibel I, Shnell M, et al: Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 54: 1214-1223, 2011.
11. Samson SL and Bajaj M: Potential of incretin-based therapies for non-alcoholic fatty liver disease. J Diabetes Complications 27: 401-406, 2013.
12. Levine B and Kroemer G: Autophagy in the pathogenesis of disease. Cell 132: 27-42, 2008.
13. Singh R, Kaushik S, Wang Y, et al: Autophagy regulates lipid metabolism. Nature 458: 1131-1135, 2009.
14. Ding WX, Li M, Chen X, et al: Autophagy reduces acute ethanol-induced hepatotoxicity and steatosis in mice. Gastroenterology 139: 1740-1752, 2010.
15. Choi SE, Lee SM, Lee YJ, et al: Protective Role of Autophagy in Palmitate-Induced INS-1 beta-Cell Death. Endocrinology 150: 126-134, 2009.
16. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001
17. Farrell GC and Larter CZ: Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43: S99-S112, 2006
18. Mizushima N, Yoshimori T and Levine B: Methods in Mammalian Autophagy Research. Cell 140: 313-326, 2010.
19. Day CP and James OF: Steatohepatitis: a tale of two 'hits'? Gastroenterology 114: 842-845, 1998.
20. Gomez-Lechon MJ, Donato MT, Martinez-Romero A, Jimenez N, Castell JV and O'Connor JE: A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact 165: 106-116, 2007.
21. Marathe CS, Rayner CK, Jones KL and Horowitz M: Glucagon-like peptides 1 and 2 in health and disease: a review. Peptides 44: 75-86, 2013.
22. Musso G, Gambino R and Cassader M: Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 48: 1-26, 2009.
23. Zhang L, Yang M, Ren H, et al: GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK. Liver Int 33: 794-804, 2013.
24. Mells JE, Fu PP, Sharma S, et al: Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol 302: G225-G235, 2012.
25. Gupta NA, Kolachala VL, Jiang R, et al: The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis. Am J Pathol 181: 1693-1701, 2012.
26. Škop V, Cahová M, Papáčková Z, et al: Autophagy-lysosomal pathway is involved in lipid degradation in rat liver. Physiol Res 61: 287-297, 2012.